CRISPR gene-editing cancer therapy tested in human for the first time
A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique.On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical trial at the West China Hospital, also in Chengdu.
It was just the latest in a line of recent firsts for China, following on the heels of the first Crispr-edited monkeys in early 2014, and the first Crispr-edited human embryos last May. Earlier clinical trials using cells edited with a different technique have excited clinicians. The introduction of CRISPR, which is simpler and more efficient than other techniques, will probably accelerate the race to get gene-edited cells into the clinic across the world, says Carl June, who specializes in immunotherapy at the University of Pennsylvania in Philadelphia and led one of the earlier studies. June thinks ”this is going to trigger ‘Sputnik 2.0’, a biomedical duel on progress between China and the United States, which is important since competition usually improves the end product”.
June is the scientific adviser for a planned US trial that will use CRISPR to target three genes in participants’ cells, with the goal of treating various cancers. He expects the trial to start in early 2017. And in March 2017, a group at Peking University in Beijing hopes to start three clinical trials using CRISPR against bladder, prostate and renal-cell cancers. Those trials do not yet have approval or funding.
Lu’s trial received ethical approval from a hospital review board in July. Injections into participants were supposed to begin in August but the date was pushed back, Lu says, because culturing and amplifying the cells took longer than expected and then the team ran into China’s October holidays.
The researchers removed immune cells from the recipient’s blood and then disabled the PD-1 coding gene in them using CRISPR–Cas9, which normally puts the brakes on a cell’s immune response and allows cancers to take advantage of to proliferate. Lu’s team then cultured the edited cells, increasing their number, and injected them back into the patient, who has metastatic non-small-cell lung cancer. The hope is that the edited cells, without PD-1, will attack and defeat the cancer.
According to Lu the treatment went smoothly, and that the participant will get a second injection. Team declined to give details because of patient confidentiality. The plan is to treat a total of ten people, who will each receive either two, three or four injections. It is primarily a safety trial, and participants will be monitored for six months to determine whether the injections are causing serious adverse effects. Lu’s team will also watch them beyond that time to see if they seem to be benefiting from the treatment.
Other oncologists are excited about CRISPR’s entry onto the cancer scene as many noted the incredible potential this strategy could bring to the table giving that using antibodies that neutralize PD-1 have successfully put lung cancer in check, boding well for a CRISPR-enabled attack on the protein. However some do question whether this particular trial will succeed. The process of extracting, genetically modifying and multiplying cells is “a huge undertaking and not very scalable”, says Naiyer Rizvi of Columbia University Medical Center in New York City. “Unless it shows a large gain in efficacy, it will be hard to justify moving forward.” He doubts it will be superior to the use of antibodies, which can be expanded to unlimited quantities in the clinic. Lu says that this question is being evaluated in the trial, but that it’s too early to say which approach is better.
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. To find out more about the cookies we use, see our Privacy Policy .
